Key facts
- This page summarizes Ilya M. Rachman's Form 4 filing for Immix Biopharma, Inc. (IMMX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2025, 18:49.
Ilya M. Rachman - 10 Dec 2025 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)
- Reporting relationship
- CEO and Chairman, Director
- Issuer ticker
- IMMX
- Reported as of
- 10 Dec 2025
- Net transaction value
- +$4,976
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2025, 18:49:30 UTC
- Prior SEC filing
- 17 Sep 2025
- Next SEC filing
- 29 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ilya Rachman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ilya M. Rachman filed Form 4 for Immix Biopharma, Inc. (IMMX) on 10 Dec 2025.
Change
- Previous filing in this sequence was filed on 17 Sep 2025.
- Current net transaction value: +$4,976.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001889334
Primary reporting owner
Rachman Ilya M
- Relationship
- CEO and Chairman, Director
- Address
- C/O IMMIX BIOPHARMA, INC., 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES
- Signature
- /s/ Ilya Rachman
- Signature date
- 10 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMMX
transaction
Common Stock
Purchase
- Transaction value
- $4,976
- Shares
- +746
- Change %
- +0.07%
- Price
- $6.67*
- Shares after
- 1,141,683
- Date
- 10 Dec 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.